Less cancer-related imaging in Department of Veterans Affairs (VA) health system

Lower Use of Cancer-Related Imaging in VA Health System
Lower Use of Cancer-Related Imaging in VA Health System

(HealthDay News) -- Cancer-related imaging use is lower in the Department of Veterans Affairs (VA) health care system than in fee-for-service Medicare, and use is not associated with geographic variation, according to research published in the Dec. 2 issue of the Annals of Internal Medicine.

J. Michael McWilliams, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues conducted an observational analysis to compare average use and geographic variation in use of cancer-related imaging between fee-for-service Medicare and the VA health care system. Medicare and VA utilization data were linked to cancer registry data for the period 2003 to 2005. Participants were older men with lung, colorectal, or prostate cancer and included 34,475 traditional Medicare beneficiaries and 6,835 VA patients.

The researchers found that in the VA versus the Medicare cohort the adjusted annual use of cancer-related imaging was lower (price-weighted count, $197 versus $379 per patient; P < 0.001). In addition, the VA cohort had lower annual use of advanced imaging for prostate cancer at low risk for metastasis ($41 versus $117 per patient; P < 0.001). The magnitude of geographic variation in cancer-related imaging use was similar for the VA and Medicare cohorts.

"Use of cancer-related imaging was lower in the VA health care system than in fee-for-service Medicare, but lower use was not associated with less geographic variation," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs